scholarly journals Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Daihua Deng ◽  
Jun Zhou ◽  
Min Li ◽  
Siyin Li ◽  
Lan Tian ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Retrospective Study ◽  
Combination Therapy ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis

2019 ◽  
Vol 46 (10) ◽  
pp. 1365-1368 ◽  
Author(s):  
Mihir D. Wechalekar ◽  
Aurélie Najm ◽  
Douglas J. Veale ◽  
Vibeke Strand
Keyword(s):  
Rheumatoid Arthritis ◽  
Retrospective Study ◽  
Synovial Tissue ◽  
Multicenter Study ◽  
Delphi Survey ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Tissue Biopsy ◽  
Group Report ◽  
Disease Modifying

Objective.The Outcome Measures in Rheumatology (OMERACT) synovial tissue biopsy (STB) working group initiated an international effort to standardize STB analyses, define consensual items to inform treatment choices, and predict responses in rheumatoid arthritis (RA).Methods.(1) A Delphi survey to determine items for STB analyses. (2) A multicenter retrospective study of STB data in patients with RA posttreatment with biological disease-modifying antirheumatic drugs.Results.The Delphi survey identified 18 STB analyses items. Consensus on histological markers was achieved in the OMERACT 2018 SIG.Conclusion.Six markers were identified for examination in a multicenter study designed to define an OMERACT-endorsed set of STB markers to predict responses to treatment.

scholarly journals AB0282 CLINICAL EFFECTIVENESS OF ABATACEPT MONOTHERAPY OR ABATACEPT CONCOMITANT METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS PATIENTS PREVIOUSLY TREATED WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (bDMARDs)

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1440.2-1440
Author(s):  
N. Márquez Pete ◽  
M. D. M. Maldonado Montoro ◽  
C. Pérez Ramírez ◽  
R. Cáliz Cáliz ◽  
A. Jiménez Morales
Keyword(s):  
Rheumatoid Arthritis ◽  
Combination Therapy ◽  
Disease Duration ◽  
Clinical Effectiveness ◽  
Methotrexate Therapy ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Eular Response ◽  
Aba Therapy ◽  
Disease Modifying

Background:Concomitant use of methotrexate (MTX) in abatacept (ABA) therapy is associated with good clinical response in patients with rheumatoid arthritis (RA) who are naïve to biological disease-modifying antirheumatic drugs (bDMARDs)1,2. However, it is unclear when abatacept is used in patients with prior bDMARDs use3.Objectives:We compared the effectiveness of abatacept monotherapy versus abatacept combined with methotrexate therapy in rheumatoid arthritis patients with prior bDMARDs use.Methods:Retrospective cohorts study. Rheumatoid arthritis patients treated with abatacept between 2009 and 2019 (n=86). Socio-demographic, clinical and pharmacological characteristics of patients were collected. We compared clinical effectiveness between ABA monotherapy patients (n=49) and abatacept concomitant methotrexate therapy patients (n=37), prior treated with bDMARDs. The effectiveness was measured according toThe European League Against Rheumatism(EULAR) response withDisease Activity Score(DAS28) like satisfactory (DAS28<3.2) or unsatisfactory (DAS28≥3.2), after 12 months of ABA therapy in RA patients.Results:49 RA patients have been evaluated in ABA monotherapy group; 83.67% (41/49) were women, disease duration was 16 (10-22) years and age of RA diagnosis was 48 (38.25-57.00). Concomitants glucocorticoids were administrated in 81.63% (40/49). Rheumatoid factor (RF) was positive in 75.51% (37/49) patients and cyclic citrullinated peptide antibodies (ACPA) in 71.43% (35/49). At 12 months, 40.82% (20/49) of patients had satisfactory EULAR response.In the combination therapy group, the age of RA diagnosis was 42.5 (35.75-53.50), 75.68% (28/37) were women and the disease duration was 12 (7-21) years. 89.19% (33/37) had concomitants glucocorticoids and the RF was positive in 72.97% (27/37) of patients. EULAR response was satisfactory at 12 months in 43.24% (16/37) of patients. No difference in treatment effectiveness was found in patients receiving abatacept in combination therapy with MTX compared with ABA monotherapy (p=0.829; IC95=0.35-2.35).Conclusion:Abatacept plus methotrexate therapy did not improve the effectiveness in rheumatoid arthritis patients with prior bDMARDs use, compared with abatacept monotherapy.References:[1]Genovese M, Schiff M, Luggen M, Becker J, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Annals of the rheumatic diseases. 2008;67(4):547-54.[2]Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020.[3]Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge E-M, Pavelka K, et al. Rituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology. 2016;55(2):230-6Disclosure of Interests:None declared

scholarly journals Profil de la polyarthrite rhumatoïde en consultation rhumatologique à Lomé (Togo)

2017 ◽  
Vol 13 (15) ◽  
pp. 125 ◽  
Author(s):  
Kakpovi K. ◽  
Koffi-Tessio V. ◽  
Houzou P. ◽  
Fianyo E. ◽  
Kolou M. ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Retrospective Study ◽  
Rheumatoid Factor ◽  
Median Duration ◽  
Carpal Bones ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Polyarthrite Rhumatoïde ◽  
The Mean ◽  
Disease Modifying

Objective: To determine epidemiological, clinical, therapeutic aspects and outcomes of rheumatoid arthritis (RA) in rheumatologic consultation at lome (Togo). Patients and method: This was retrospective study carried out from 1 stJanuary 1990 to 31 stDecember 2015 in the rheumatology department. The study included all patients suffered from RA in rheumatologic consultations and who fulfilled the 2010 ACR and EULAR’s criteria. Results: Ninety two (77 women and 15 men) out of 25.992 patients (0.3%) examined in 25 years had suffered from RA. The mean age at admission was 42 years (range: 17-82 years). The median duration of the diseases was four years (range: 14days – 20 days). The diseases onset was polyarticular with 86% of the patients and oligoarticular with the thirteen others (14%). The proximal interphalangeal (PIP) joints and metacarpophalangeal (MCP) joints are involved in 81,5 % of cases; and the wrists in 77,2% of cases. The rheumatoid hip was observed in four patients. Forty-two of the patients (45,6%) presented RA deformities. Bilateral MCP and IPP joint early erosion was observed in 36 patients (39,1%) and bilateral carpal diffuse osteoporosis in 44 patients (47,8%). The ankylosis of the carpal bones was observed in 26 patients (28,2 %). Rheumatoid factor was positive in 44% of patients. Methotrexate was the most commonly disease-modifying antirheumatic drugs used in 44,4% of the patients. The disease was improved in 89% of patients. Conclusion: Rheumatoid arthritis seems relatively rare in Togo. It’s diagnosis is often made at the established phase and methotrexate remains the cornerstone of the treatment.

Sign in / Sign up

Export Citation Format

Share Document